| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 17.6MM | +89% |
| Gross Profit | 16.8MM | - |
| Cost Of Revenue | 725K | -15% |
| Operating Income | -4MM | -87% |
| Operating Expenses | 20.9MM | - |
| Net Income | -1.5MM | -95% |
| R&D | 26.6MM | +12% |
| G&A | 8.2MM | +16% |
| Amortization | 18K | -5% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Aclaris Therapeutics ( NASDAQ:ACRS ) Full Year 2023 Results Key Financial Results Revenue: US$31.2m (up 5.0% from FY...
The latest analyst coverage could presage a bad day for Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ), with the analysts...
Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. “Returnin